• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . The CD38+HLA-DR+ T cells with activation and exhaustion characteristics as predictors of severity and mortality in COVID-19 patients

tetano

Editor, Senior Moderator
Front Immunol


. 2025 Apr 30:16:1577803.
doi: 10.3389/fimmu.2025.1577803. eCollection 2025. The CD38[SUP]+[/SUP]HLA-DR[SUP]+[/SUP] T cells with activation and exhaustion characteristics as predictors of severity and mortality in COVID-19 patients

Qiuyue Long[SUP] #[/SUP][SUP] 1 2 [/SUP], Shixu Song[SUP] #[/SUP][SUP] 1 2 [/SUP], Jianbo Xue[SUP] #[/SUP][SUP] 3 [/SUP], Wenyi Yu[SUP] 3 [/SUP], Yaolin Zheng[SUP] 1 2 [/SUP], Jiwei Li[SUP] 4 [/SUP], Jing Wu[SUP] 1 2 [/SUP], Xiaoyi Hu[SUP] 2 3 [/SUP], Mingzheng Jiang[SUP] 1 2 [/SUP], Hongli Ye[SUP] 1 2 [/SUP], Binghan Zheng[SUP] 1 2 [/SUP], Minghui Wang[SUP] 1 2 [/SUP], Fangfang Wu[SUP] 1 2 [/SUP], Ke Li[SUP] 5 [/SUP], Zhancheng Gao[SUP] 1 2 3 [/SUP], Yali Zheng[SUP] 1 2 6 [/SUP]



Affiliations
Abstract

Background: The COVID-19 pandemic remains a global health challenge. Severe cases often respond poorly to standard treatments, highlighting the necessity for novel therapeutic targets and early predictive biomarkers.
Methods: We utilized flow cytometry to analyze peripheral immune cells from healthy, bacterial pneumonia patients, and COVID-19 patients. The expansion of activated T cells (CD38[SUP]+[/SUP]HLA-DR[SUP]+[/SUP]), monocytes, and myeloid-derived suppressor cells (MDSCs) were detected and correlated with clinical outcomes to evaluate prognostic potential. The single-cell RNA sequencing (scRNA-seq) was applied to characterize the critical cell subset associated with prognosis and elucidate its phenotype in COVID-19.
Results: We revealed a significant increase in CD38[SUP]+[/SUP]HLA-DR[SUP]+[/SUP] T cells in non-survivor COVID-19 patients, establishing them as an independent risk factor for 28-day mortality. The scRNA-seq analysis identified the CD38[SUP]+[/SUP]HLA-DR[SUP]+[/SUP] T cell as a terminally differentiated, Treg-like subset exhibiting both activation and exhaustion characteristics. This subset presented the highest IL-6 and IL-10 mRNA levels among all T-cell subsets. Further functional analysis demonstrated its enhanced major histocompatibility complex class II (MHC-II) cross-signaling and correspondingly enriched cytoskeletal rearrangement processes. In addition, there was dysregulated NAD[SUP]+[/SUP] metabolism in CD38+HLA-DR+ T cells via scRNA-seq, accompanied by elevated adenosine and decreased NAD[SUP]+[/SUP] levels in serums from COVID-19 patients.
Conclusions: We identified the selective expansion of CD38[SUP]+[/SUP]HLA-DR[SUP]+[/SUP] T cells as a novel prognostic indicator for COVID-19 outcomes. These cells' unique activated-exhausted phenotype, along with their impact on NAD[SUP]+[/SUP] metabolism, provides new insights into COVID-19 immunopathogenesis.

Keywords: CD38+HLA-DR+ T cells; COVID-19; T cells; mortality risk factor; single-cell transcriptomics.

 
Back
Top Bottom